# A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors

Source: [Physics : nature.com subject feeds](https://www.nature.com/articles/s41467-026-78202-8) · 2026-11-13 · Physics
Page: https://themorning.science/story/a-microfluidic-fluorescence-lifetime-screening-platform-bridges-in-vitro-and-in-3d854fdc10bb36ca
Kind: research · Impact: low

## In brief

- A microfluidic fluorescence lifetime screening platform is reported on nature.com.
- The platform is described as bridging in vitro and in vivo formats.
- The authors report using it to discover Amyloid β aggregation inhibitors.

## Why it matters

It describes a screening method for Amyloid β aggregation inhibitors that connects test-tube and in vivo formats, which may matter to researchers working on amyloid-related drug discovery.

## Coverage

- [A microfluidic fluorescence lifetime screening platform bridges in vitro and in vivo formats and enables discovery of Amyloid β aggregation inhibitors](https://www.nature.com/articles/s41467-026-78202-8) — Physics : nature.com subject feeds, 2026-11-13

Tags: microfluidics, fluorescence lifetime, amyloid beta, drug screening, aggregation inhibitors

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science